ESMO2016
Cancer market commentary: Roche’s Tecentriq muscles into NSC...
BMS’s Opdivo and Merck’s Keytruda have been the sole PD-1 immunotherapies for the last two years, but Roche’s Tecentriq gained approval in May this year in urothelial carcinoma, a cancer of
